Atrial Fibrillation During Pregnancy: A 9-month Period with Limited Options

Overview

Journal Herzschrittmacherther Elektrophysiol

Date 2021 Apr 6

PMID 33822238

Citations 1

Authors

Konstantinos Iliodromitis

Jacek Kociszewski

Harilaos Bogossian

Affiliations

Soon will be listed here.

Abstract

Pregnancy is a physiological condition with reversible hemodynamic, neurohormonal and coagulation changes to the maternal body during this 9‑month period. The occurrence of atrial fibrillation (AF) is altogether rare among pregnant women, but necessitates immediate treatment und further work-up. Despite numerous pharmacological and invasive therapeutic modalities for AF in non-pregnant patients, very few options are considered safe enough for the fetus and the mother during pregnancy. Commonly used medications such as beta blockers, calcium channel antagonists, antiarrhythmic drugs and anticoagulation therapy must be carefully individualized according to the week of gestation and possible underlying comorbidities of the mother, thus highlighting the importance of an interdisciplinary evaluation by a cardiologist and a gynecologist. The current review summarizes the existing knowledge and treatment options for AF in pregnancy and suggests a simplified algorithm for this clinical constellation.

Citing Articles

The Challenge of Managing Atrial Fibrillation during Pregnancy.

Luca F, Oliva F, Abrignani M, Russo M, Parrini I, Cornara S Rev Cardiovasc Med. 2024; 24(10):279.

PMID: 39077579 PMC: 11273119. DOI: 10.31083/j.rcm2410279.

References

Chugh S, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin E . Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2013; 129(8):837-47. PMC: 4151302. DOI: 10.1161/CIRCULATIONAHA.113.005119. View

Mou L, Norby F, Chen L, ONeal W, Lewis T, Loehr L . Lifetime Risk of Atrial Fibrillation by Race and Socioeconomic Status: ARIC Study (Atherosclerosis Risk in Communities). Circ Arrhythm Electrophysiol. 2018; 11(7):e006350. PMC: 6053683. DOI: 10.1161/CIRCEP.118.006350. View

Ko D, Rahman F, Schnabel R, Yin X, Benjamin E, Christophersen I . Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. Nat Rev Cardiol. 2016; 13(6):321-32. PMC: 5579870. DOI: 10.1038/nrcardio.2016.45. View

Chapman A, Abraham W, Zamudio S, Coffin C, Merouani A, Young D . Temporal relationships between hormonal and hemodynamic changes in early human pregnancy. Kidney Int. 1998; 54(6):2056-63. DOI: 10.1046/j.1523-1755.1998.00217.x. View

Mahendru A, Everett T, Wilkinson I, Lees C, Mceniery C . A longitudinal study of maternal cardiovascular function from preconception to the postpartum period. J Hypertens. 2014; 32(4):849-56. DOI: 10.1097/HJH.0000000000000090. View

Bader R, BADER M, ROSE D, Braunwald E . Hemodynamics at rest and during exercise in normal pregnancy as studies by cardiac catheterization. J Clin Invest. 1955; 34(10):1524-36. PMC: 438730. DOI: 10.1172/JCI103205. View

Robson S, Hunter S, Boys R, Dunlop W . Serial study of factors influencing changes in cardiac output during human pregnancy. Am J Physiol. 1989; 256(4 Pt 2):H1060-5. DOI: 10.1152/ajpheart.1989.256.4.H1060. View

Hunter S, Robson S . Adaptation of the maternal heart in pregnancy. Br Heart J. 1992; 68(6):540-3. PMC: 1025680. DOI: 10.1136/hrt.68.12.540. View

Jarvis S, Shibata S, Bivens T, Okada Y, Casey B, Levine B . Sympathetic activation during early pregnancy in humans. J Physiol. 2012; 590(15):3535-43. PMC: 3547268. DOI: 10.1113/jphysiol.2012.228262. View

10.

Greenwood J, Scott E, Stoker J, Walker J, Mary D . Sympathetic neural mechanisms in normal and hypertensive pregnancy in humans. Circulation. 2001; 104(18):2200-4. DOI: 10.1161/hc4301.098253. View

11.

CHESLEY L . Plasma and red cell volumes during pregnancy. Am J Obstet Gynecol. 1972; 112(3):440-50. DOI: 10.1016/0002-9378(72)90493-0. View

12.

PRITCHARD J . CHANGES IN THE BLOOD VOLUME DURING PREGNANCY AND DELIVERY. Anesthesiology. 1965; 26:393-9. DOI: 10.1097/00000542-196507000-00004. View

13.

Jepson J . Endocrine control of maternal and fetal erythropoiesis. Can Med Assoc J. 1968; 98(18):844-7. PMC: 1924099. View

14.

Robson S, Hunter S, Moore M, Dunlop W . Haemodynamic changes during the puerperium: a Doppler and M-mode echocardiographic study. Br J Obstet Gynaecol. 1987; 94(11):1028-39. DOI: 10.1111/j.1471-0528.1987.tb02286.x. View

15.

Ducas R, Elliott J, Melnyk S, Premecz S, daSilva M, Cleverley K . Cardiovascular magnetic resonance in pregnancy: insights from the cardiac hemodynamic imaging and remodeling in pregnancy (CHIRP) study. J Cardiovasc Magn Reson. 2014; 16:1. PMC: 3882291. DOI: 10.1186/1532-429X-16-1. View

16.

Gowda R, Punukollu G, Khan I, Wilbur S, Navarro V, Vasavada B . Lone atrial fibrillation during pregnancy. Int J Cardiol. 2003; 88(1):123-4. DOI: 10.1016/s0167-5273(02)00360-1. View

17.

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B . 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38):2893-2962. DOI: 10.1093/eurheartj/ehw210. View

18.

Bateman B, Heide-Jorgensen U, Einarsdottir K, Engeland A, Furu K, Gissler M . β-Blocker Use in Pregnancy and the Risk for Congenital Malformations: An International Cohort Study. Ann Intern Med. 2018; 169(10):665-673. PMC: 6854680. DOI: 10.7326/M18-0338. View

19.

Bergman J, Lutke L, Gans R, Addor M, Barisic I, Cavero-Carbonell C . Beta-Blocker Use in Pregnancy and Risk of Specific Congenital Anomalies: A European Case-Malformed Control Study. Drug Saf. 2017; 41(4):415-427. PMC: 5878198. DOI: 10.1007/s40264-017-0627-x. View

20.

Duan L, Ng A, Chen W, Spencer H, Nguyen J, Shen A . β-Blocker Exposure in Pregnancy and Risk of Fetal Cardiac Anomalies. JAMA Intern Med. 2017; 177(6):885-887. PMC: 5818837. DOI: 10.1001/jamainternmed.2017.0608. View